BF Biosciences Limited, Pakistan’s pioneering biopharmaceutical manufacturer, has announced the successful launch of its latest innovation, Zeptide® (Tirzepatide) — an advanced treatment for Type 2 Diabetes and Obesity, now available in a convenient, pre-filled syringe format.
In a notice sent to PSX today, BFBIO says that Tirzepatide, approved by the US Food and Drug Administration (FDA), is a synthetic polypeptide that acts as a dual agonist for GLP-1 and GIP receptors, offering a breakthrough approach in managing blood glucose levels and promoting weight reduction.
The new Zeptide® pre-filled syringe, developed and produced at BF Biosciences’ state-of-the-art European technology-based facility, ensures precision, safety, and ease of use, eliminating dosing errors and improving patient compliance.
“With Zeptide®, we are proud to bring a world-class therapeutic option to Pakistani patients,” said a company spokesperson. “This innovation reinforces our commitment to developing essential, locally manufactured biologics that meet international quality standards.”
Zeptide® has undergone rigorous testing for quality, structure, and potency at a leading biological mass spectrometry facility in the United States and at a national university in Pakistan, ensuring global-level validation.
The development of Zeptide® is a significant milestone achieved through the company’s IPO proceeds utilization plan, demonstrating BF Biosciences’ dedication to reinvesting in Pakistan’s healthcare ecosystem.
With Pakistan ranking among the highest globally in diabetes prevalence, the need for accessible and effective treatment options is urgent. Over 9 million Pakistanis remain undiagnosed, while 57% of women and 41% of men are overweight or obese, increasing their risk of Type 2 diabetes by up to seven times.
It is pertinent to mention that BF Biosciences Limited is already leading the GLP1 generic of semaglutide through its brand Sematide and is most prescribed GLP1 in the market.
As the 1st Biopharmaceutical Plant in Pakistan, BF Biosciences Limited has remained committed to the production of essential medicines for the treatment of HCV, Cancer, Cardiology, Diabetes, nephrology and other therapeutic areas for over a decade. We are confident that the launch of Zeptide® will have a positive impact on the Company’s growth and will further strengthen our mission to address critical, unmet patient needs, the notice further added.
